SYMBICORT AEROSPHERE Drug Patent Profile

Which patents cover Symbicort Aerosphere, and when can generic versions of Symbicort Aerosphere launch?

Symbicort Aerosphere is a drug marketed by Astrazeneca and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and ninety-two patent family members in thirty-two countries.

The generic ingredient in SYMBICORT AEROSPHERE is budesonide; formoterol fumarate. There are twenty-two drug master file entries for this compound. Additional details are available on the budesonide; formoterol fumarate profile page.

DrugPatentWatch^® Generic Entry Outlook for Symbicort Aerosphere

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 28, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for SYMBICORT AEROSPHERE

International Patents:	192
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SYMBICORT AEROSPHERE

US Patents and Regulatory Information for SYMBICORT AEROSPHERE

SYMBICORT AEROSPHERE is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes			Y
Astrazeneca	SYMBICORT AEROSPHERE	budesonide; formoterol fumarate	AEROSOL, METERED;INHALATION	216579-001	Apr 28, 2023		RX	Yes	Yes

International Patents for SYMBICORT AEROSPHERE

When does loss-of-exclusivity occur for SYMBICORT AEROSPHERE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Montenegro

Netherlands

Norway

Philippines

Poland

Portugal

Russian Federation

San Marino

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering SYMBICORT AEROSPHERE around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	2435025
Hungary	E031283
Taiwan	201109049	Compositions for respiratory delivery of active agents and associated methods and systems
Australia	2010253950

Supplementary Protection Certificates for SYMBICORT AEROSPHERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435025	CR 2019 00032	Denmark		PRODUCT NAME: KOMBINATION AF GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERER ELLER SOLVATER DERAF, OG FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, ENANTIOMERE ELLER SOLVATER DERAF; REG. NO/DATE: EU/1/18/1339 20181220
2435025	2019026	Norway		PRODUCT NAME: KOMBINASJON AV GLYKOPYRROLAT (INKLUDERT EVENTUELLE FARMASOEYTISK AKSEPTABLE SALTER, ESTERE ELLER ENANTIOMERER DERAV) OG FORMOTEROL (INNBEFATTENDE HVILKE SOM HELST FARMASOEYTISK AKSEPTABLE SALTER, ESTERE ELLER ENANTIOMERER DERAV); REG. NO/DATE: EU/1/18/1339 20190104
2435024	LUC00208	Luxembourg		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435024	C02435024/01	Switzerland		PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021

Investment Scenario and Fundamentals Analysis for SYMBICORT AEROSPHERE

Last updated: February 20, 2026

What is the Current Market Position of SYMBICORT AEROSPHERE?

SYMBICORT AEROSPHERE is a combination inhaled corticosteroid and long-acting beta-agonist (ICS-LABA) for asthma and COPD management. Marketed primarily by AstraZeneca, it holds a significant share in the global respiratory drug market. The drug is approved in multiple regions, including the U.S., Europe, and emerging markets, with approximately $1.2 billion in global sales in 2022, representing a compound annual growth rate (CAGR) of 4% from 2018 to 2022 (EvaluatePharma, 2022).

What Are the Key Market Drivers?

• Rising prevalence of asthma and COPD globally.
• Increasing adoption of inhaled therapies over oral treatments.
• Growing awareness and improved diagnostic capabilities.
• Approval of new indications and formulations.

How Does SYMBICORT AEROSPHERE Compare Competitively?

Attribute	SYMBICORT AEROSPHERE	Competitors (e.g., Advair Diskus, Dulera)
Delivery Method	Breath-actuated inhaler	Diskus, MDI
Formulation	Aerosol	Diskus, MDI
Peak Sales (2022)	~$1.2 billion	Advair ($3.3 billion), Dulera (~$300 million)
Patent Expiry (Approximate)	2026–2028 (varies)	Advair expired 2020

The aerosol delivery method differentiates SYMBICORT AEROSPHERE, with concerns over generic competition post-patent expiry impacting future sales.

What Are the Patent and Regulatory Risks?

• Patent expiry around 2026–2028, opening the market to generics or biosimilars.
• Regulatory approvals depend on regional health agencies, with some markets requiring additional clinical data for post-approval labeling extensions.
• Ongoing patent litigation could either delay or reinforce market exclusivity.

What Are the Sales & Revenue Outlooks?

Analysts project a slow to moderate growth due to patent cliff pressures. Expected sales decline by 7–10% annually post-2028 absent new formulations or indications. The current revenue base is expected to plateau around 2024-2025 unless AstraZeneca introduces improved versions or expands indications.

What Is the R&D Pipeline and Innovation Potential?

• New inhaler delivery devices with improved dosing accuracy.
• Investigational formulations targeting severe asthma and COPD with reduced corticosteroid doses.
• Potential approval of triple therapy (ICS-LABA-LAMA) combining SYMBICORT components with additional agents.
• The pipeline indicates an emphasis on enhanced delivery and combination therapies to extend market life cycle.

How Do Market and Regulatory Trends Affect Investment?

• Increasing focus on biosimilar and generic inhaled therapies threatens future revenues.
• Regulatory bodies, especially the FDA and EMA, favor innovative delivery devices, potentially allowing market extension.
• Eco-friendly inhaler alternatives attract regulatory and reimbursement advantages.

What Are the Financial and Strategic Risks?

• Patent expiration risks leading to generic competition.
• Pricing pressures in regulated markets.
• Dependence on AstraZeneca’s pipeline success for growth.
• Potential shifts in treatment guidelines favoring alternative therapies.

What Are the Key Investment Considerations?

• Current revenue reliance on established formulations.
• Patent expiry looming in the next two years.
• Innovation pipeline showing incremental improvements.
• Market risks from generic competition and pricing regulation.
• Opportunities from expanding indications and delivery platforms.

Key Takeaways

SYMBICORT AEROSPHERE maintains a strong market position with around $1.2 billion in sales as of 2022. The product faces patent expiration in the 2026–2028 window, risking significant revenue decline unless offset by pipeline innovations or new indications. The product's competitive advantage lies in its inhaler delivery method and formulation but faces increasing competition and regulatory challenges. AstraZeneca's strategic focus on reformulation and pipeline expansion remains critical to sustaining future growth.

5 FAQs

Q1: When does SYMBICORT AEROSPHERE's patent likely expire?
A1: Patent protection is expected to expire around 2026–2028, varying by region.

Q2: How vulnerable is SYMBICORT AEROSPHERE to generic competition?
A2: High, post-patent expiry; generic entries usually follow within one to two years.

Q3: Are there ongoing efforts to improve or expand SYMBICORT AEROSPHERE’s formulations?
A3: Yes, AstraZeneca is developing enhanced inhalers and triple combination therapies for broader indications.

Q4: How significant are regulatory approvals in influencing sales?
A4: Critical; approval of new indications and formulations can extend product life and revenue streams.

Q5: What is the outlook for SYMBICORT AEROSPHERE’s market share?
A5: Expected to decline gradually unless countered by innovation, pipeline growth, or market expansion.

References

1. EvaluatePharma. (2022). World Preview 2022: Outlook to 2027. Retrieved from https://www.evaluatepharma.com
2. AstraZeneca. (2022). SYMBICORT Product Information. Retrieved from https://www.astrazeneca.com
3. U.S. Food and Drug Administration. (2023). Approved Drugs and Patent Data. Retrieved from https://www.fda.gov